About Us

Group Milestone

Date Content  
2002
  1. Formulated the first tissue engineering skin product registration standard in China in 2002
2003
  1. Completed the first clinical trial of tissue engineering product in China in 2003
2004
  1. Passed the first format inspection of tissue engineering product in China in 2004
2007
  1. Received the first registration certificate of tissue engineering product in China in 2007
2009
  1. Researched and developed the world’s first bio-engineered cornea that entered clinical trial in 2009
2011
  1. Tissue engineering skin received the first prize of national scientific and technological progress award in 2011
2012
  1. Established the first tissue engineering industrial base in China in 2012
2015
  1. The world’s first bio-engineered cornea "Acornea" with registration certificate was launched on market
  2. China’s first tissue-engineered anal fistula repair material "Asiunin" got approved and was launched on market
  3. CRMI received “2015 Best Social Responsibility Brand Award"
  4. "Acornea" was rated as one of the "2015 Top 10 China Medicinal Biotech Progresses" and "2015 Top Ten Achievements of China’s Ophthalmology"
As of September 1, 2016, CRMI Group has applied for over 140 patents in total at domestically and internationally, owns over 70 patents, has applied for over 170 registered trademarks, owns over 100 exclusive rights of the registered trademark, and owns 4 copyrights.
2016
  1. In March, CRMI officially entered into Hainan Baoao Lecheng International Medical and Tourism Pilot Zone.
  2. In September, collaborating with the University of Hong Kong, CRMI received HK$ 4.4 million subsidy from the Hong Kong Innovation and Technology Commission for a translational research project entitled “Automated Bioreactors for Expanding and Monitoring Mesenchymal Stem Cells”
  3. In September, CRMI entered into a strategic cooperation with China National Scientific Instruments and Materials Corporation (“CSIMC”) in Beijing.
  4. CRMI has established multiple regional immune/stem cell processing centres in Hong Kong, Tianjin, Suzhou, Changzhou. In addition, for facilitating cell therapy applications in anti-aging, HKIRC was established in Mira Mall, Tsim Sha Tsui, Hong Kong.

IR Contact

China Regenerative Medicine International Limited

A:

10/F, Dah Sing Financial Center, 108 Gloucester Road, Wan chai, Hong Kong

E: info@crmi.hk|

T: +852 3966 8388 |

F: +852 2802 0026